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Abstract
Background Chronic kidney disease is almost
always accompanied by anaemia. Erythropoietin-
stimulating agents (ESA) can increase haemoglobin
concentration and thus reduce the frequency of
anaemia-related complications including the cardio-
vascular events.
Aim The aim of the study was to collect prospective
data on 12-month standard ESA therapy used in
haemodialyzed patients in selected CEE countries as
well as on cardiovascular complications, iron status
and anaemia treatment.
Patients and methods Fifty centres in 3 countries
participated in the study. A group of 398 haemodial-
ysed stable patients (M-231, F-167) aged 19–90 years
(57.5 ± 14.7) on standard ESA therapy for chronic
renal anaemia were recruited. Twelve-month prospec-
tive data on iron parameters, ESA therapy and
cardiovascular events were collected. The use of iron,
folic acid and blood transfusions were also assessed.
Patient were divided into three groups according to
ESA therapy start: group A—patients who received
ESA after start of haemodialysis, group B—patients
who received ESA within 3 months from the day of
first haemodialysis and group C—patients who had
received ESA more than 3 months before haemodial-
ysis. Chi2 test for qualitative data and Kruskall–Wallis
test for quantitative data with p \ 0.05 were used in
statistical analysis.
Results At prestudy period, the mean weekly dose of
ESA in group C was statistically lower than in the
remaining two groups (3,823 ± 3,169 vs. 5,276 ±
2,915 and 6,427 ± 3,441 units/week, p \ 0.001), but
during prospective phase of the study the doses did not
differ among groups A, B and C. No major fluctuation
of ESA administration schedule was observed during
the study in the groups; however, at majority of visits,
the mean frequency of ESA administration in group C
was statistically higher than in groups A and B. At
baseline visit, the haemoglobin concentration in group
A patients (10.86 ± 1.34 g/dL) was slightly lower
than in group B (11.26 ± 1.43 g/dL) and group C
(10.98 ± 1.35 g/dL) (p = 0.025), but at subsequent
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visits these differences disappeared and mean haemo-
globin concentration was stable around 11 g/dL.
Ferritin concentration increased from 280 ± 241 at
baseline to 506 ± 405 at month 12, and no important
differences in the groups were observed. The other
haematological parameters (haematocrit, iron concen-
tration) remained stable during the entire study. The
frequency of blood transfusion and total volume of
blood in group C were lower than in groups A and B.
During the prospective 12-month follow-up, 23
(5.8 %) of the patients died and 35 (8.8 %) were
transplanted. No differences in death or transplanta-
tion rate were observed among groups A, B and C. The
number of patients with adverse events, serious
adverse events or drug-related adverse events in all
groups was similar. In conclusion, ESA therapy
increased haemoglobin concentration and no major
differences in haematological parameters among the
groups were observed during the entire study irre-
spective of early versus late start. Mortality, cardio-
vascular events or other adverse events were similar
among the groups during the observation period;
however, the limitation of the study is the sample size.
Keywords Anaemia  Central and Eastern Europe 
Haemodialysis  Cardiovascular events
Introduction
Anaemia has remained one of the most characteristic
and visible manifestations of chronic renal failure for
over 150 years. Typically, it is a normocytic and
normochromic anaemia with bone marrow of normal
cellularity. Anaemia has been defined as a reduction in
one or more of the major red blood cell measurements:
haemoglobin concentration (Hb), haematocrit or eryth-
rocyte count. The pathogenesis of anaemia of chronic
kidney disease is multifactorial [1]. Although inade-
quate production of erythropoietin is the most impor-
tant factor in the pathogenesis of anaemia in chronic
kidney disease, other factors play a role and contribute
to mild anaemia that is often present despite the use of
recombinant human erythropoietin or other erythro-
poiesis stimulating agents (ESA). Renal anaemia has a
number of potentially deleterious effects, including
impairment of tissue oxygen delivery, increased
cardiac output and left ventricular hypertrophy predis-
posing to congestive heart failure cognitive decline,
sexual dysfunction and depression of immune respon-
siveness [2]. Moreover, cardiovascular disease is a
leading cause of death in both chronic kidney disease
(CKD) and dialysed patients [3, 4]. Silverberg et al. [5]
proposed the term ‘cardio-renal anaemia syndrome’ to
stress the importance of mutual relations in the popu-
lations suffering from CKD and/or CHF. Administra-
tion of ESA to increase Hb concentrations from lower
values to [10–11 g/dL significantly reduces the car-
diovascular complications of renal anaemia and reduces
the frequency of chronic heart failure and hospitaliza-
tion among predialysis and dialysis-dependent patients
[6, 7]. Recent randomized trials (CHOIR, CREATE and
TREAT) [8–10] clearly showed that targeting higher Hb
levels in CKD has been linked with increased morbidity
and mortality particularly from cardiovascular causes.
There might have been several mechanisms of such
unexpected harm, besides increased viscosity through
an increase in haematocrit. Also a recently published
study in Veteran Administration predialysis patients
showed lowered risk of hospitalization (by 17 %) and of
transfusion by 29 % when ESA were initiated early (Hb
10–11 g/dL) versus late (Hb level 9–9.9 g/dL) [11].
We designed a multicenter, open-label, observa-
tional study to assess the impact of early versus late
referral on the effectiveness of renal anaemia treatment
with ESA in 3 groups of haemodialysis patients (treated
less than 3 months of ESA before HD, treated more
than 3 months of ESA before HD and not treated with
ESA before HD) with special interest on the medical
history (early/late referral, cardiovascular events) and
safety in a large Central and Eastern European countries
(CEE). We presented the baseline data of this study
previously [12]. In the 12-month follow-up, we looked
at the current renal anaemia management, iron param-
eters and haemoglobin in haemodialysed patients in
relation to the early or late referral in CEE countries in
everyday clinical practice. Additionally, we assessed
the number of cardiovascular (CV) events, deaths and
hospitalization for CV or other events.
Patients and methods
Patients suitable for the study should fulfil the
following inclusion criteria: stable haemodialysed
patients with renal anaemia who are no longer than
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12 months on haemodialysis and who are on ESA
therapy; patients who had no fluctuation of Hb more
than 2 g/dL/month within the last 3 months of ESA
treatment; aged C18 years; who gave signed the
written informed consent. Fifty public centres in 3
countries participated in the study, predominantly
non-academic. A total of 398 haemodialysed patients
(M-231, F-167) aged 19–90 years (57.5 ± 14.7) on
standard ESA therapy for chronic renal anaemia were
recruited. The primary kidney diseases were the
following: diabetic nephropathy (n = 75; 18.84 %),
glomerulonephritis (n = 64; 16.08 %), hypertensive
nephropathy (n = 61; 15.33 %), interstitial nephri-
tis (n = 79; 19.85 %), ADPKD (n = 38; 9.55 %)
and other (n = 33; 8.29 %) or unknown (n = 48;
12.06 %). Concomitant diseases were as follows:
diabetes (n = 102; 25.63 %), hypertension (n = 354;
88.94 %), coronary heart disease (n = 113; 28.39 %),
chronic heart failure (n = 115; 28.89 %), left ventric-
ular hypertrophy (n = 192; 48.24 %), peripheral
occlusive disease (n = 50; 12.56 %), dyslipidaemia
(n = 171; 42.96 %), secondary hyperparathyroidism
(n = 142; 35.68 %), while recorded prestudy cardio-
vascular event included myocardial infarction (n =
41; 10.30 %), coronary artery bypass grafting (n = 7;
1.76 %), percutaneous coronary interventions (n =
14; 3.52 %), stroke (n = 19;4.77 %) and transient
ischemic attack (n = 19; 4.77 %).
The following prospective parameters had been
collected during the study and were analysed: Hb
concentration, haematocrit, iron concentration, ferri-
tin, blood pressure, ESA therapy (dose and frequency),
medications (including iron supplementation), all
major CV events (myocardial infarction-MI, percuta-
neous coronary interventions-PCI, coronary artery
bypass grafting, stroke, transient ischemic attacks-
TIA), adverse events, deaths. The data were collected
using electronic data capture system. Data were
verified for logical and medical consistency according
to the instructions provided in CTAP. In case of
inconsistencies, the data query was generated and was
sent for investigator’s review. A part of problems was
resolved; however, some queries were not addressed
by investigators. Unresolved issues are related to
missing data allowing to allocate patient to specific
study group (15 patients), discrepancies between
laboratory results and acceptable range of results,
and AE description. All available and logically
acceptable data were analysed.
Patients were divided into three groups:
Group A Patients not treated with ESA before the
start of dialysis
Group B Patients who had started ESA therapy with-
in three months from the start of dialysis
Group C Patients who had started the ESA therapy
more than three months before the start of
dialysis
Comparisons were performed for all patients allocated
to one of the groups. Patients without allocation were
excluded from analysis.
Statistical analysis
The data recorded in the database were provided for
analysis in EXCEL format. The data were analysed in
SAS statistical software. v2 test was used for analysis of
qualitative data and Kruskall–Wallis test for quantita-




The study was performed on 398 patients from 50
centres in Latvia, Poland and Serbia. There were 231
(58 %) males and 167 (42 %) females aged 19–90
years (57.5 ± 14.7). A total of 269 patients completed
12 months of therapy. The reasons for study discon-
tinuation were provided previously [12]. Based on the
start dates of ESA and dialysis therapy, patients were
allocated to groups A, B and C:
• Group A—180 subjects (106 males, 74 females)
aged 19–86 years (56.2 ± 14.4 years).
• Group B—164 subjects (94 males, 70 females)
aged 19–90 years (57.6 ± 14.9 years).
• Group C—39 subjects (21 males, 18 females) aged
20–86 years (61.8 ± 16 years).
No statistically significant differences among groups
A, B and C according to age and sex distributions were
found. Fifteen patients could not be classified into any of
the groups and were excluded from comparative
analysis. Groups A, B and C did not differ according
to baseline: arterial blood pressure, body weight or
height and BMI.
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Prospective laboratory results during study visits
Haematology assessment was done at each study visit.
It consisted of evaluation of the following parameters:
haemoglobin, haematocrit, serum iron and ferritin
concentration.
Haemoglobin concentration
Except from baseline evaluation, the mean haemoglo-
bin concentration did not differ significantly among
the groups A, B and C (Fig. 1).
Haematocrit
Mean haematocrit in group B patients from baseline to
visit 3 was statistically higher than in the remaining
two groups. Mean haematocrit in all three groups was
not statistically different starting from visit 4 onwards
(Fig. 2).
Serum iron concentration
Mean serum iron concentration in all three groups was
stable during all visits. No statistically significant
differences in serum iron were observed at any time of
the study (Fig. 3).
Ferritin concentration
In all three groups, ferritin concentration tended to
increase during the study. Except for visits 2 and 6,




values in all patients tested
and mean values in groups
A, B and C at subsequent
visits
Fig. 2 Maximal, minimal
and mean haematocrit in all
patients tested in groups A,
B and C at subsequent visits
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ferritin concentration among groups A, B and C
(Fig. 4).
Prospective concomitant treatment for anaemia
Concomitant treatment for anaemia consisted of iron,
folic acid and blood transfusions. Majority of patients
received iron therapy (86, 7.5 % of them were given
oral iron, the remaining intravenous iron) and folic
acid therapy (68 %). Blood transfusions were per-
formed in 31 % of subjects (Fig. 5, 6).
The mean number of blood transfusion per patient in
group A was statistically significantly higher than that of
the remaining two groups (2.7 ± 2.45 vs. 1.75 ± 1.28
and 1.4 ± 0.7). The mean of the total volume of blood
transfused to one patient in group A was significantly
higher than that of groups B and C (respectively,
1,329 ± 1,201 vs. 940 ± 803 and 590 ± 248 mL, p =
0.01). There was no statistically significant difference in
the number of patients treated with iron, folic acid or
given blood transfusion between groups (p = 0.95,
p = 026, and p = 0.56, respectively).
Fig. 3 Serum iron concentration (lmol/l). Maximal and minimal values in all patients tested and mean values in groups A, B and C at
subsequent visits
Fig. 4 Ferritin (mg/dL).
Maximal and minimal
values in all patients tested
and mean values in groups
A, B and C at subsequent
visits
Int Urol Nephrol (2014) 46:71–82 75
123
When we look at the haematological status of the
patients, we found that 17 % of the patients had Hb
\10 g/dL during the study period (ranging from 14 to
24 %), whereas 7 % had Hb[13 g/dL (ranging from 0
to 11 %). To correct the calculated EPO resistance for
differences in Hb levels, EPO resistance index (ERI)
was determined as the ratio EPO/Hb [defined as
weekly EPO dose (U/kg b.w.) divided by Hb level
(g/dL)]. We found that ERI was 9.35 ± 7.37.
We also looked at the CRP (assessed by
laboratories using low-sensitivity method) and
found that median CRP was 4.7 (0–622 mg/L)
and there were no statistically significant changes
between visits. Of the patients, 26 % had CPR
[10 mg/L, whereas 40 % of the patients had CRP
[6 mg/L .
Prospective concomitant treatment
for hypertension and CHD
Statins were administered to 34 % of patients, and
ACE inhibitors or AT1 blockers were administered to
34 % of patents as well. Most patients (82 %) received
other antihypertensive medication (Table 1). The rate
of patients on ACE or AT1 blockers in group B was
statistically higher than that in groups A and C.
Prospective other concomitant medication
Totally 827 concomitant medications were reported in
the database. The most frequently administered con-
comitant medication was vitamin B12 (24.6 %),
acetylsalicylic acid (18.6 %) and Calcium carbonicum
(18.1 %).
Prospective blood pressure
The mean systolic and diastolic blood pressure in the
whole group of patients did not change during the
study period (Fig. 7). Neither the systolic blood
pressure nor the diastolic blood pressure differs among
groups A, B and C at any visit.
The mean dialysis time was 705 ± 94 min. Group
A patients were on dialysis statistically significantly
longer than patients from groups B and C (respectively,
721 ± 92 vs. 691 ± 92 and 704 ± 102 months, p =
0.02). No changes in dialysis adequacy (KT/V) were












iron therapy folic acid therapy blood transusion
received treatment did not receive treatment
Fig. 5 Concomitant treatment for anaemia in all study patients.
There were no statistically significant differences in the rate of
patients on iron or folic acid therapy nor in those who received
blood transfusion among groups A, B and C (Fig. 6)
Fig. 6 The rate of patients
on iron therapy, folic acid
therapy or patients who
received at least one blood
transfusion during the study
in groups A, B and C
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C did not differ according to dialysis adequacy at any
study visit.
Prospective adverse events excluding common
dialysis-related AE
The protocol predefined the adverse events of special
interest. Within 12 months of the study, 8 episodes of
myocardial infarction in 7 patients were recorded. One
patient had coronary artery bypass, and 3 patients had
3 episodes of percutaneous coronary intervention.
Stroke occurred in 6 patients including one patient
with two episodes. The frequency of these adverse
events did not differ among groups A, B and C
(Table 2). Other AE were reported in 174 (43.7 %)
patients. A total of 486 AE were reported. Mean
number of adverse events per patient was 1.22. The
most frequent adverse events were pneumonia (16
episodes), urinary tract infection (16 episodes), fever
(12 episodes) and bronchitis (10 episodes). No differ-
ences in the number of patients with AE and the mean
number of AE episodes among groups A, B and C
were noted (Table 2). A total of 187 serious adverse
events were reported in 99 patients (Table 3). Mean
number of the serious adverse events episodes in all
patients was 0.47. There were no differences in the
number of patients with the episode or mean number
of episodes among groups A, B and C (Table 4).
Investigator assessed that in 33 patients the event was
study drug related. Neither differences in the number
of patients with this kind of episode nor the mean
number of episodes were observed among groups A, B
and C (Table 2). Twenty-three patients died and 35
patients received kidney transplantation. The death
rate and transplantation rate in all groups did not differ
(Table 3).
Discussion
For the first time, we demonstrated that in EEC
majority of patients with chronic kidney disease
receive ESA therapy shortly before or after the start
of dialysis treatment. In addition, we have found that
despite iron supplementation (86 % of the studied
population), serum iron remained stable as well as the
total weekly dose of NeoRecormon (median dose for
group A was 6,000 IU per week at baseline and
Table 1 Summary of hypertension and CHF treatment
Total (N = 398) Group A (N = 180) Group B (N = 164) Group C (N = 39) p
N % N % N % N %
No. of patients receiving statins 137 34.4 60 33.3 60 36.5 17 43.6 NS
No. of patients receiving ACE
inhibitors/AT1 blockers
135 33.9 52 28.9 69 42.1 14 35.9 0.038
No. of patients receiving other
antihypertensive medication
327 82.1 147 81.7 143 87.2 36 92.3 NS
Fig. 7 Predialysis blood
pressure (min diastolic,
mean diastolic, mean
systolic and max systolic)
during the subsequent study
visits in all patients
participating in the study
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4,000 IU after 12 months, for group B 5,000 IU and
4,250 IU, for group C 6,000 IU and 6,000 IU per
week, respectively). Except for visits 4 and 5, there
were no differences in mean weekly dose of NeoR-
ecormon between study groups. However, ferritin
concentration increased from 280 ± 241 at baseline to
506 ± 405 at month 12 and no important differences
in the groups were observed, while the other haema-
tological parameters (haematocrit, haemoglobin)
remained stable during the entire study. The frequency
of blood transfusion and total volume of blood in
group C were lower than in groups A and B and
probably contributed to the rise in serum ferritin
together with intravenous iron supplementation. There
was no evidence of excessive iron load, as we are fully
aware of the fact that iron overdose might also
contribute to adverse outcomes in randomized trials
of anaemia correction in CKD as stressed by van
Buren et al. [13]. During prospective 12-month
follow-up, 23 (5.8 %) of the patients died and 35
(8.8 %) were transplanted. No differences in death or
transplantation rate were observed among groups A, B
and C. The number of patients with adverse events,
serious adverse events or drug-related adverse events
in all groups was similar. As shown previously, at the
start of dialysis, mean haemoglobin value is lower
than at the diagnosis of the disease (respectively,
9.26 ± 1.7 vs 10.3 ± 2.3 g/dL) [12]. At the beginning
of ESA therapy, mean haemoglobin value is
9.24 ± 1.4 g/dL close to the value in the TREAT
study in diabetic CKD population [10]. During all
subsequent study visits, mean haemoglobin value in
the whole study group was stable and varied from
11.04 to 11.26 g/dL, again perfectly fitted in the new
postulated target. Group A patients entered the study
with lower haemoglobin concentration than the
remaining groups; however, the differences shortly
disappeared. During the first 3 months of the study, B
patients had higher haematocrit than the remaining
groups. Our study was designed before the results of
the TREAT trial were available. Presented data reflect
reimbursement policy in EEC. No differences in
adverse events profile including serious adverse
events, drug-related adverse events or cardiovascular
events were observed among groups A, B and C. The
death rate and kidney transplantation rate in all groups
were similar. Therefore, our data support the concept
that the adequate erythropoietin treatment does not
enhance the risk of cardiovascular complications in
HD population. Since our study was performed only in
the EEC, therefore, it is very difficult to discuss our
findings with other trials involving Europe (both
Western and Eastern), USA or being global as
TREAT. In the ORAMA trial prevalent, HD or CKD
patients were randomized to either standard clinical
care or computerized clinical decision support, and
comparison between current management of renal
anaemia in both CKD and dialysis patients in Eastern
and Western European countries was performed [14].
In the GAIN study [15] involving only HD subjects
treated with any ESA for at least 12 weeks, and for
18 months with epoetin beta, there were regional
differences between Balkan, Baltics, and Eastern,
Southern and Western Europe. However, these data
were not analysed.
Reasonable dose of ESA to keep Hb target of 10 or
10.5 g/dL or a range of 10–12 g/dL has recently been
postulated [16] although more radical position has
been taken by Ajay K Singh, the principal investigator
of the CHOIR study [9]. He suggests that avoiding use
of ESAs in managing anaemia in non-dialysis patients
with CKD is now the soundest approach [17]. An
individualized approach to every patient and a proper
control of increase in Hb, protecting from overshoot-
ing (not exceeding Hb 12 g/dL) may be a reasonable
approach in most of patients with CKD. However, in
our study, we found that 7 % (range from 0 to 11 %)
occasionally had Hb [13 g/dL, which required cau-
tion. At the last two visits, none of the patient had Hb
over 13 g/dL, whereas 17 % of the patients had Hb
below 10 g/dL. In the prospective observational study
RISCAVID study (‘RISchio CArdiovascolare nei
pazienti afferenti all’Area Vasta In Dialisi’), per-
formed on the 753 prevalent HD patients in the
north-western area of Tuscany, Italy, the impact of
haemoglobin levels, as continuous or categorical
variable, on fatal and non-fatal CV events was not
statistically significant [18]. However, in non-adjusted
analysis, haemoglobin levels \11 g/dL were associ-
ated with the highest risk for all-cause mortality and
fatal/non-fatal CV events, while patients with haemo-
globin levels [11 g/dL had the lowest all-cause
mortality risk which was comparable to the reference
group (no ESAs). In the RISCAVID study focused on
the ESA resistance and its relation to CV events, they
found that ESA responsiveness can be considered a
strong prognostic factor in HD patients and seems to
be tightly related to protein-energy wasting and
80 Int Urol Nephrol (2014) 46:71–82
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inflammation. In our study, we looked for the possible
relations between early versus late ESA treatment and
CV events. Our data suggest that predialysis ESA
treatment have virtually no effect on the anaemia
practice pattern in prevalent HD population in EEC.
The early versus late ESA therapy in CKD does not
influence the rate of CV events and mortality in
prevalent HD population in EEC. The strength of our
study is the fact that this is the largest and the most
recent study performed in EEC, with similar reim-
bursement policy in these 3 countries. Furthermore,
we performed a study on relatively homogeneous for
race, geography, medical care and HD management
population. Before TREAT results became available,
we started to treat anaemia relatively late with low
doses of ESA providing iron supplementation in vast
majority of patients. Last January in USA the bundling
system, which is similar to our reimbursement policy,
was introduced. As reported at the Annual Dialysis
Congress in San Antonio in February 2012, the use
of ESA dropped significantly together with a rise
in iron. In addition, percentage of Hb levels over
13 g/dL declined significantly, while Hb below 10 g/dL
remained stable (personal communication). Our resu-
lts indicate that relatively low use of ESA together
with iron supplementation may yield expected results,
that is, achieved Hb levels with the lowest possible
adverse events, particularly cardiovascular. However,
we are not aware of the pharmacoeconomic analysis
till date. Moreover, our ERI was much lower than that
reported for the US population by Kotanko et al. [19].
They also stated that lower ERI was associated with
better anaemia control.
Our study has some important limitations. Of note
is the very low mortality in our population studied,
5.7 % in the whole group and low number of all CV
events after 12 months. In the RISCAVID study, the
mortality after 36 months was 27.5 % and 208 out of
753 patients experienced a fatal/non-fatal CV event.
Moreover, this was not a randomized trial, and
potential confounders might have influenced our
results. Previously, we reported a retrospective and
baseline data, and we stressed the differences at the
baseline among 3 groups studied as defined per
protocol [12]. We would like to stress that vast
majority of the patients studied had a-v fistula as their
vascular access (n = 320), only 27 had permanent
catheter and 38 had temporary catheter (for 6 patients
no data are available). There were no grafts as vascular
access in the population studied. It may also contribute
to the low mortality, as well as the fact that patients
enroled in clinical trials are more compliant and
healthier than the prevalent patients in every HD unit.
In conclusion, ESA therapy increased haemoglobin
concentration and no major differences in haemato-
logical parameters among the groups were observed
during the entire study irrespective of early versus late
start. Duration of ESA treatment before HD does not
affect mortality, cardiovascular events or other
adverse events among the groups during the observa-
tion period. Adequate anaemia treatment is the most
sound approach yielding the best desirable outcomes.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the
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Appendix
Latvia: Regina Baufale, Natalija Bidzina,Inara Bus-
mane, Vera Grotkere, Tatjana Kozlova, Guna Legzdi-
na, Linda Micule, Gita Saumane-Baza, Aldis Spudass,
Ligita Zepa.
Poland: Danuta Antczak-Je˛drzejczak, Hanna
Augustyniak-Bartosik, Wacław Bentkowski, Alicja
Brylowska-Markowicz, Edward Ciechanowicz-Lew-
kowicz, Krzysztof Dziewanowski, Jacek Felisiak,
Piotr Firczyk, Mirosław Grzeszczyk, Zbigniew Hruby,
Marzena Janas, Krzysztof Jarze˛bski, Marian Klinger,
Arkadiusz Lewartowski, Justyna Matulewicz-Gil-
ewicz, Olech Mazur, Danuta Ostrowska-Reguła,
Marita Piechowska, Jan Pulchny, Roman Radziszew-
ski, Bolesław Rutkowski, Jacek Sobolewski, Roman
Stankiewicz, Anna Strus´, Arkadiusz Szwedowicz,
Ewa Trafidło, Jerzy Wiatrow, Rafał Wnuk, Danuta
Zaremba-Drobnik, Danuta Zwolin´ska.
Serbia: Jovan Bakovic,Ivana Budosan,Vidojko
Djordjevic, Rosa Jelacic, Dragisa Jevremovic, Ljiljana
Komadina, Djoko Maksic, Igor Mitic, Vidosava Nesic,
Svetlana Pejanovic, Steva Pljesa, Nenad Rakic, Miomir
Stojanovic, Ljubisa Veljancic.
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